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The study included 28 patients with ES-SCLC who under-1. Focal article
Rui Liu, Shu Lin He, Yuan Chen Zhao, Hong Gang Zheng, Cong
Huang Li, Yan Ju Bao, YingGangQin,WeiHou, Bao JinHua. Chi-
nese herbal decoction based on syndrome differentiation as
maintenance therapy in patients with extensive-stage small-
cell lung cancer: an exploratory and small prospective cohort
study. Evid Based Complement Alternat Med 2015;2015:601067.
doi:10.1155/2015/601067. Epub 2015 Mar 1.
2. Aim
The aim of this study is to evaluate the effect of tra-
ditional Chinese herbal medicine (TCHM) and the impact
of treatment duration on both progression-free survival
(PFS) and postprogression survival (PPS) in patients with
∗ Korean Medicine Clinical Trial Center, Kyung Hee University Korean
Korea.
E-mail address: julcho@naver.com
http://dx.doi.org/10.1016/j.imr.2015.09.004
2213-4220/© 2015 Korea Institute of Oriental Medicine. Published by Else
(http://creativecommons.org/licenses/by-nc-nd/4.0/).extensive-stage small-cell lung cancer (ES-SCLC). Additionally,
this study attempts to reﬂect clinical practice by prescribing
individualizedTCHMon the basis of syndromedifferentiation.
3. Design
This was an exploratory and small prospective cohort study
using TCHM as the maintenance therapy alongside standard
comprehensive treatments for ES-SCLC.
4. SettingMedicine Hospital, 1 Hoegi-dong, 02447 Dongdaemun-gu, Seoul,
went TCHM treatment at the Oncology Department of
Guang’anmen Hospital, China Academy of Chinese Medical
Sciences, Beijing, China from January 2010 to March 2012.
vier. This is an open access article under the CC BY-NC-ND license
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Table 1 – TCHM treatment duration and participants
number in each phase
Number of TCHM
treatment
Median
months(range)
Number of
patients
Taking TCHM during
and after
chemotherapy
4.7 (2.6-11.1) 16
Taking TCHM after
chemotherapy
2.4 (1-10.7) 12
Total treatment time 12.2 (3.2-27) 28
≥ 12 mo 17.2 (12.4-27) 15
< 12 mo 5.3 (3.2-10.5) 13
First phase
treatment time
3.4 (1-11.1) 28
≥ 3 mo 6.7 (3.4-11.1) 15
< 3 mo 1.8 (1-3) 13
Second phase
treatment time
7.0 (1-22.5) 27
≥ 7 mo 12.7 (7.3-16.7) 13
< 7 mo 2.6 (1-7.0) 14. Leem/Chinese Medicine and Cancer Survival
. Participants
total of 28 patients [22 men, 6 women; median age, 61 years
42−75)] were enrolled. The median number of metastatic
ites was 2 (range, 1–6). All participants had undergone ﬁrst-
ine chemotherapy, consisting of four to six cycles of either
isplatin or carboplatin combined with etoposide, and were
onsidered responsive to therapy. Themajor symptoms of the
articipants were fatigue (75%) and cough (64%).
The participants were divided into two groups: (1) Group A:
6participantsundergoingTCHMduringandafter chemother-
py and (2) Group B: 12 participants undergoing TCHM only
fter, but not during, chemotherapy.
The inclusion criteria were as follows:1 (1) The patients
hould have a histologically or cytologically conﬁrmed diag-
osis of ES-SCLC according to Veterans Administration Lung
tudy Group staging criteria. This included patients with
leural or pericardial effusions and/or supraclavicular lym-
hadenopathy. (2) They should have an effective response
fter ﬁrst-line chemotherapy, including complete response,
artial response, or stable disease. (3) They should have a com-
inationof platinumandetoposide asﬁrst-line chemotherapy.
4) They should have a life expectancy of at least 3 months.
5) They should have the ability to swallow and retain oral
edication. (6) They should have a World Health Organiza-
ion performance status of 0–2, aged > 18 years and < 80 years.
7) They should have adequate hematologic, hepatic, and renal
unction and coagulation parameters.
. Intervention
1) Individualized TCHM was prescribed based on syndrome
differentiation. The median total duration of treatment
was 12.2 months (3.2–27 months).
2) The period encompassing both treatment and follow-up
was divided into two phases, as shown below. The treat-
ment period is detailed in Table 1. (i) First phase: From the
beginning of TCHM treatment until cancer progression. (ii)
Second phase: From cancer progression until either death
or the end of the study (September 2013)
3) The basic syndromes and the respective prescriptions for
these syndromes are as follows:
Qi deﬁciency: radix Astragali 45 g/d, radix Pseudostellariae
15 g/d, Atractylodes 15 g/d, Wolﬁporia extensa 20g/d, and
pericarpium Citri reticulatae 6 g/d.
Yin deﬁciency: Adenophora elata 30g/d, radix Ophiopogonis
12g/d, mulberry leaf 12 g/d, Scrophularia ningpoensis 12g/d,
and gypsum 45g/d.
Phlegm syndrome: fructus Trichosanthis 20g/d, Allium
macrostemon 15g/d, almond 10g/d, Platycodon grandiﬂorus
30g/d, and Pinellia ternata 10g/d—this prescription was
modiﬁed depending on the individual’s symptoms, signs,
and status.
4) Comprehensive treatment consisted of TCHM, chemother-
apy, and radiotherapy.
5) At least 1 year of TCHM treatment was recommended;
however, the duration of treatment was decided by the
participants.TCHM, traditional Chinese herbal medicine.
7. Main outcome measures
The primary endpoint was PFS, deﬁned as the “time from the
beginning of CHD treatment until disease progression or death
from any cause and conﬁrmed on the last CT before progres-
sive disease.”1
The secondary endpoints were as follows: (1) PPS; (2) 24-
week PFS rate; (3) overall survival (OS); (4) 1-year survival
rate; and (5) functional assessment. PPS was deﬁned as “the
time from disease progression to death or study conclusion
(September 2013).”1 OS was deﬁned as “the time from the
date of ﬁrst-line treatment until death or the study deadline.”1
Adverse events were also recorded.
8. Main results
(1) The median total follow-up period was 14 months (range:
8–27 months). All patients survived the ﬁrst phase. The
median follow-up period during the ﬁrst phase was 3.4
months (range, 1–11.1 months). During the second phase,
21 patients died due to cancer progression, while one died
due to infection and one due to heart failure. The 24-week
PFS rate was 60.7%.
(2) The median PFS periods were 7 months in Group A and
6.2 months in Group B; this difference was not signiﬁ-
cant [hazard ratio = 0.88; 95% conﬁdence interval (CI) =
0.41–1.36].
(3) During the ﬁrst phase, the median PFS period was signiﬁ-
cantly longer in patients who had received TCHM for ≥ 3
months than in those who received TCHM for < 3 months
(8.7 months vs. 4.5 months; hazard ratio = 0.52; 95% CI
0.41–0.99).
(4) During the second phase, the median PPS period was sig-
niﬁcantly longer in patients who had received TCHM for ≥
7 months than in those who received this treatment for <
7 months (11.7 months vs. 5.1 months; hazard ratio = 2.32;
95% CI = 1.90–2.74).
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(5) During the entire follow-up period, the median PPS period
was signiﬁcantly longer in patients who had received
TCHM for ≥ 12 months than in those who had done so
for < 12 months (13.1 months vs. 5.6 months; hazard ratio
= 2.34; 95% CI = 1.91–2.77).
(6) Adverse events: During chemotherapy, bone marrow sup-
pression was lower in Group A (TCHM and chemotherapy)
than in Group B (chemotherapy alone), as evidenced by
the differing rates of leukopenia (44% vs. 75%) and anemia
(19% vs. 50%). Fatigue was also less common in Group A
(19% vs. 91%).
9. Authors’ conclusions
The authors argued that, in cases where ﬁrst-line chemother-
apy is effective, TCHM may prolong PPS and PFS of ES-SCLC
patients. Furthermore, they contended that concurrent treat-
mentwith TCHMandﬁrst-line chemotherapywas particularly
effective, as it protected against bonemarrow suppression and
fatigue. They also claimed that the effect of TCHM is related to
the duration of treatment and recommended implementation
of TCHM as soon as possible, in order to lengthen the treat-
ment duration. They also suggested the minimum duration
of TCHM treatment before progression to exceed 3 months
and the total duration to exceed 12 months. This study may
provide a basis for future TCHM clinical trials that employ
syndrome differentiation.
10. Comment/critique
Lung cancer is a major cause of cancer-related death.1 It is
of two main types: non-small-cell lung cancer (NSCLC) and
small-cell lung cancer (SCLC);2 approximately 15%of lung can-
cers are of the SCLC kind.1 The 5-year survival rate in NSCLC is
about 25%,2 whereas inSCLC it is 1–5%,mainly because 60–70%
of SCLC patients have metastases in multiple sites; common
loci include the bonemarrow, brain, bone, and liver.2 Both sur-
vival time and quality of life (QOL) are important factors in
lung cancer treatment,2 while the cancer stage is the most
important factor in cancer prognosis.
In recent years, the number of studies addressing can-
cer treatment using traditional East Asian medicine has
increased.3 These investigations have addressed several
pressing problems, such as improving treatment response
rate, reducing the toxicity and side effects of standard can-
cer therapy, and elucidating unpredicted interactions between
conventional therapy and herbal medicines.3 In addition,
several studies have investigated the effect of traditional
East Asian medicine on QOL in cancer patients. For exam-
ple, in a systematic review of the use of TCHM to treat
cancer-related fatigue, the Jianpi Yiqi Huatan decoction or
Ganoderma lucidum was found to reduce cancer-related fatigue
signiﬁcantly.4 In a pragmatic acupuncture trial conducted on
302 breast cancer patients, those receiving acupuncture treat-
ment experienced a better QOL than the usual-care group,
as evaluated using the Functional Assessment of Cancer
Therapy—Breast Cancer.5 The general fatigue score, evaluatedIntegr Med Res ( 2 0 1 5 ) 256–259
using the Multidimensional Fatigue Inventory, was also lower
in the acupuncture group.5
In a randomized clinical trial addressing the use of herbal
medicine in 118 NSCLC patients, those receiving the Feiji
decoction, for soothing the liver, as well as both psychother-
apy and chemotherapy experienced an improved QOL as
compared to those receiving chemotherapy alone. QOL was
assessed using the European Organization for Research and
Treatment of Cancer QOL Questionnaire LC-43.6
Epidermal growth factor receptor tyrosine kinase inhibitor
(EGFR-TKI)-targeted treatment is the standard therapy for
advanced SCLC.7 In a systematic review, it was found that the
use of TCHM in combination with EGFR-TKI resulted in higher
1- and 2-year survival rates than did the use of EGFR-TKI
alone. Moreover, TCHM improved or stabilized Karnofsky per-
formance status and reduced treatment toxicity.7 In another
systematic review involving 15 trials and 862 patients, oral
TCHM was found to improve QOL, as well as diminish anemia
and neutropenia, in Stage III/IV NSCLC patients.8
However, fewer studies have investigated the use of tradi-
tional East Asian medicine as treatment for SCLC, which has
a mean expected OS of 6–8 weeks in the absence of treat-
ment. With combination chemotherapy using platinum and
etoposide, the OS increases to a mere 7–11 months, due to
a relatively short PFS of 4–6 months.1 The cancer recurs in
almost all ES-SCLC patients, causing death in 95%of cases.1 As
chemotherapy in SCLCdoes little to improve survival rates and
has debilitating side effects,9,10 the major goals for clinicians
treating this type of cancer are (1) prolonging life expectancy
and (2) easing side effects.1 In a randomized clinical trial
conducted in China, patients treated using Xidan soup com-
bined with chemoradiotherapy had signiﬁcantly improved OS
compared to those treated with chemoradiotherapy alone;11
the median OSs were 11.1 months and 7.6 months, respec-
tively. Additionally, the 1-, 2-, and 3-year survival rates were
38.6% versus 18.2%, 18.1% versus 4.5%, and 13.6 versus 2.3%,
respectively.11 Although TCHM has been shown to improve
QOL in a systematic review, the authors of the focal article
claimed that higher-quality studies are needed to draw objec-
tive conclusions regarding the efﬁcacy of TCHM in ES-SCLC.1
This was the ﬁrst paper on TCHM that mentioned syn-
drome differentiation and treatment duration in the context
of ES-SCLC.1 The authors claimed that the overall 24-week
PFS rate was higher in their study than in a historical control
(60.7% vs. 41%), and believe that this suggests that individual-
ized TCHM therapy improves prognosis in ES-SCLC patients
who have responded to ﬁrst-line chemotherapy. Thus, this
article suggests that TCHM can form a part of cancer treat-
ment and advocates adopting a new clinical research model
that employs a personalized prescription method. The over-
all median PPS was 7.6 months; this was also longer than
the previously reported postrecurrencemedian survival of 4–5
months.1 Moreover, they found that TCHM treatment duration
is a key factor in cancer treatment, because TCHM therapy in
excess of 3 months increased PFS, implying improved sensi-
tivity to second-line therapy.By contrast, this study also had several limitations. First,
the stage of chemotherapy duringwhich TCHM treatmentwas
administered did not have a signiﬁcant effect on PFS com-
pared to chemotherapy alone. Therefore, although a longer
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11. Ran WH, Huang CS, Wang EY, Yong RB, Huang XP, Bo Y, et al.. Leem/Chinese Medicine and Cancer Survival
reatment duration improved clinical outcome, the efﬁcacy of
CHM should be investigated further. Moreover, this was an
xploratory study that contained many statistical analyses,
nd hence, the possibility of a type-1 error cannot be excluded.
or this reason, a future study should include PFS or PPS as the
rimary outcome. Additionally, the authors did not explain
hy they selected 3 months, 7 months, and 12 months as
utoff points; it is also possible that the participants did not
ie earlier because of shorter TCHM treatment, but might in
act have stopped TCHM treatment due to death or disease
rogression. In such a case, this study does not prove that
ndividualized TCHM treatment is superior to conventional
reatment for cancer patients.
In summary, the results of this cohort study should be inter-
reted with care, and future clinical research should focus
n the causal relationship between treatment duration and
linical outcome in SCLC.
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